| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6299 | 2012 |
| Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş, J Mazières, B Hermes, ... New England Journal of Medicine 379 (21), 2040-2051, 2018 | 3179 | 2018 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ... The Lancet 387 (10030), 1837-1846, 2016 | 2882 | 2016 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1659 | 2015 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1044 | 2019 |
| Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ... The Lancet 387 (10026), 1415-1426, 2016 | 948 | 2016 |
| Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial G Zalcman, J Mazieres, J Margery, L Greillier, C Audigier-Valette, ... The Lancet 387 (10026), 1405-1414, 2016 | 936 | 2016 |
| Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial D Planchard, B Besse, HJM Groen, PJ Souquet, E Quoix, CS Baik, ... The Lancet Oncology 17 (7), 984-993, 2016 | 921 | 2016 |
| Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial D Planchard, EF Smit, HJM Groen, J Mazieres, B Besse, Å Helland, ... The Lancet Oncology 18 (10), 1307-1316, 2017 | 915 | 2017 |
| First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ... New England Journal of Medicine 383 (21), 2018-2029, 2020 | 779 | 2020 |
| Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives J Mazières, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ... Journal of clinical oncology 31 (16), 1997-2003, 2013 | 742 | 2013 |
| Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA oncology 4 (3), 351-357, 2018 | 713 | 2018 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 694 | 2018 |
| Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ... New England Journal of Medicine 383 (10), 931-943, 2020 | 670 | 2020 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 654 | 2020 |
| Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer BT Li, EF Smit, Y Goto, K Nakagawa, H Udagawa, J Mazières, ... New England Journal of Medicine 386 (3), 241-251, 2022 | 583 | 2022 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 545 | 2018 |
| A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407 L Paz-Ares, D Vicente, A Tafreshi, A Robinson, HS Parra, J Mazières, ... Journal of Thoracic Oncology 15 (10), 1657-1669, 2020 | 537 | 2020 |
| Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ... Journal of Clinical Oncology 38 (21), 2369, 2020 | 498 | 2020 |
| Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial D Planchard, TM Kim, J Mazieres, E Quoix, G Riely, F Barlesi, PJ Souquet, ... The Lancet Oncology 17 (5), 642-650, 2016 | 476 | 2016 |
